264 related articles for article (PubMed ID: 8479736)
21. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
22. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
[TBL] [Abstract][Full Text] [Related]
23. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
Crombach G; Zippel HH; Würz H
Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
[TBL] [Abstract][Full Text] [Related]
25. Role of Ca 125 as tumor marker in ovarian carcinoma.
Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
[TBL] [Abstract][Full Text] [Related]
26. CA 125 in ovarian cancer.
van der Burg ME; Lammes FB; Verweij J
Neth J Med; 1992 Feb; 40(1-2):36-51. PubMed ID: 1579185
[TBL] [Abstract][Full Text] [Related]
27. [Diagnosis of the recurrence of epithelial ovarian cancer with the tumor marker CA 125].
Sevelda P; Wagner G
Wien Klin Wochenschr; 1987 Nov; 99(21):768-70. PubMed ID: 3480655
[TBL] [Abstract][Full Text] [Related]
28. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
29. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
30. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
31. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol.
Pearl ML; Yashar CM; Johnston CM; Reynolds RK; Roberts JA
Gynecol Oncol; 1994 Jun; 53(3):339-43. PubMed ID: 7911444
[TBL] [Abstract][Full Text] [Related]
32. [Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer].
Hernádi Z; Molnár V; Juhász B; Pólka R; Margitai B
Zentralbl Gynakol; 1992; 114(1):6-9. PubMed ID: 1585745
[TBL] [Abstract][Full Text] [Related]
33. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
34. [Computed tomography and tumor markers as diagnostic alternatives to second-look surgery in the treatment of malignant ovarian tumors].
La Fianza A; Campani R; Dore R; Babilonti L; Torretta L
Radiol Med; 1992 Apr; 83(4):374-82. PubMed ID: 1603993
[TBL] [Abstract][Full Text] [Related]
35. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.
Lambeck AJ; Crijns AP; Leffers N; Sluiter WJ; ten Hoor KA; Braid M; van der Zee AG; Daemen T; Nijman HW; Kast WM
Clin Cancer Res; 2007 Apr; 13(8):2385-91. PubMed ID: 17438097
[TBL] [Abstract][Full Text] [Related]
36. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
37. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
38. The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study.
Gadducci A; Landoni F; Maggino T; Sartori E; Zola P; Fanucchi A
Gynecol Oncol; 1996 Nov; 63(2):234-7. PubMed ID: 8910633
[TBL] [Abstract][Full Text] [Related]
39. [Comparative study of 3 markers in ovarian cancer: CA 125, CA 19,9 and CEA].
Vigné E; Krebs B; Khater R; Mira R; Boublil JL; Jourlait A; Frenay M; Namer M
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(5):609-13. PubMed ID: 3463621
[TBL] [Abstract][Full Text] [Related]
40. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer].
Liu W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):469-72. PubMed ID: 1303823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
